Contact this trialFirst, we need to learn more about you.
Chemoradiation + Durvalumab for Lung Cancer
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is for elderly or poor-risk patients with inoperable NSCLC who have not been previously treated. It is a phase II study, which means that researchers are still determining if the treatment is effective. The treatment consists of chemoradiation (a combination of chemotherapy and radiation) followed by the immunotherapy drug Durvalumab.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.